Abstract
Tumour cells engineered to express co-stimulatory molecules on their surface provide researchers with powerful new tools to manipulate antitumour responses. It has been demonstrated that B7-1+ and B7-2+ tumour cells can elicit effective responses against their wild-type counterparts. This response is primarily mediated by CD8+ cytolytic T-lymphocytes. The co- stimulatory ability of B7-2+ tumour cells is comparable to that of B7-1+ tumour cells, though with some exceptions. However, on host antigen- presenting cells (APC), B7-2 plays a dominant role in inducing T-cell- mediated immune responses. Up-regulation of B7-2 on host APC may, therefore, present an effective means of generating potent antitumour immunity.
Original language | English (US) |
---|---|
Pages (from-to) | 677-684 |
Number of pages | 8 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 6 |
Issue number | 6 |
DOIs | |
State | Published - 1997 |
Externally published | Yes |
Keywords
- B7 co-stimulation
- T-cell activation
- Tumour immunotherapy 677-684
ASJC Scopus subject areas
- Pharmacology